# US 8,277,840 B2 · Sustained release formulation of alprazolam

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,840 B2
- Document ID: US8277840B2
- Status: Granted
- Kind: B2
- Application number: 11/996,377
- Filed: 2006-07-20
- Published: 2008-12-18
- Granted: 2012-10-02
- Earliest claimed: 2005-07-22
- Assignees: Emcure Pharmaceuticals Limited
- Inventors: Manjusha Joshi; Ganesh Vinayak Gat; Satish Ramanlal Mehta
- Web page: https://patentgrep.com/patent/US8277840B2

## CPC

- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 25/20: Hypnotics; Sedatives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed towards the preparation of extended release Alprazolam formulation. The formulation thus obtained provides an efficient mode of delivery of Alprazolam in a continuous manner.

## Claims

### Claim 1

A sustained release pharmaceutical composition comprising:
(a) a therapeutically effective amount of alprazolam,
(b) a high viscosity hydroxy-propyl-methyl cellulose (HPMC) and low viscosity hydroxy-propyl-methyl cellulose (HPMC), wherein the total amount of HPMC is about 70 mg to about 100 mg in a ratio of 70:30 to 85:15, and
(c) pharmaceutically acceptable excipients.

### Claim 2 (depends on 1)

A composition as claimed in claim 1, wherein the amount of alprazolam is between 1 mg and 5 mg.

### Claim 3 (depends on 1)

A composition as claimed in claim 1, wherein the alprazolam is a pharmaceutically acceptable salt of alprazolam.

### Claim 4 (depends on 1)

A composition as claimed in claim 1, wherein the high viscosity HPMC has about 19% to about 24% by weight of methoxy substituent, and about 4% to about 12% by weight of hydroxypropoxy substituent.

### Claim 5 (depends on 1)

A composition as claimed in claim 1, wherein the high viscosity HPMC has a viscosity of about 1500 to about 2,25,000 cp.

### Claim 6 (depends on 1)

A composition as claimed in claim 1, wherein the low viscosity HPMC has a viscosity of about 2 to about 400 cp.

### Claim 7 (depends on 1)

A composition as claimed in claim 1, wherein the low viscosity HPMC is selected from the group consisting of K3 P LV and K 100P LV.

### Claim 8 (depends on 1)

A composition as claimed in claim 1, wherein the ratio of high viscosity HPMC to low viscosity HPMC is 65:35 to 75:25.

### Claim 9 (depends on 1)

A composition as claimed in claim 1, wherein the ratio of high viscosity HPMC to low viscosity HPMC is 70:30.

### Claim 10 (depends on 1)

A composition as claimed in claim 1, wherein the composition provides a total daily dose of about 0.5 mg to about 3 mg of alprazolam.

### Claim 11 (depends on 1)

A composition as claimed in claim 1, wherein the composition is configured to release alprazolam at a rate that ranges between 20% to 40% in 4 hours to more than 70% in 14 hours of the total dose of alprazolam after the exposure to phosphate buffer having pH 6.0.+−.0.1.

### Claim 12 (depends on 1)

A composition as claimed in claim 1, wherein the Cmax occurs more than 3 hours after administration.

### Claim 13

A process for the preparation of a sustained release composition of alprazolam, comprising the steps of:
(a) mixing alprazolam with lactose and optionally coloring agents in geometric proportion;
(b) sifting the mixture to obtain homogeneous blend;
(c) adding a high viscosity hydroxy-propyl-methyl cellulose (HPMC) and low viscosity hydroxy-propyl-methyl cellulose (HPMC), wherein the total amount of HPMC is about 70 mg to about 100 mg in a ratio of 70:30 to 85:15 to the blend from step (b);
(d) granulating the blend with water to form wet mass;
(e) drying the wet mass;
(f) forming granules; and
(g) compressing to form tablet.
